Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, D-45147, Essen, Germany.
Department of Diagnostic and Interventional Radiology, Medical Faculty, University Dusseldorf, D-40225, Dusseldorf, Germany.
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):67-76. doi: 10.1007/s00259-017-3809-y. Epub 2017 Aug 24.
The aim of the present study was to assess and compare the diagnostic performance of integrated PET/MRI and MRI alone for local tumor evaluation and whole-body tumor staging of primary cervical cancers. In addition, the corresponding impact on further patient management of the two imaging modalities was assessed.
A total of 53 consecutive patients with histopathological verification of a primary cervical cancer were prospectively enrolled for a whole-body 18F-FDG PET/MRI examination. Two experienced physicians analyzed the MRI data, in consensus, followed by a second reading session of the PET/MRI datasets. The readers were asked to perform a dedicated TNM staging in accordance with the 7th edition of the AJCC staging manual. Subsequently, the results of MRI and PET/MRI were discussed in a simulated interdisciplinary tumor board and therapeutic decisions based on both imaging modalities were recorded. Results from histopathology and cross-sectional imaging follow-up served as the reference standard.
PET/MRI allowed for a correct determination of the T stage in 45/53 (85%) cases, while MRI alone enabled a correct identification of the tumor stage in 46/53 (87%) cases. In 24 of the 53 patients, lymph node metastases were present. For the detection of nodal-positive patients, sensitivity, specificity and accuracy of PET/MRI were 83%, 90% and 87%, respectively. The respective values for MRI alone were 71%, 83% and 77%. In addition, PET/MRI showed higher values for the detection of distant metastases than MRI alone (sensitivity: 87% vs. 67%, specificity: 92% vs. 90%, diagnostic accuracy: 91% vs. 83%). Among the patients with discrepant staging results in the two imaging modalities, PET/MRI enabled correct treatment recommendations for a higher number (n = 9) of patients than MRI alone (n = 3).
The present results demonstrate the successful application of integrated PET/MRI imaging for whole-body tumor staging of cervical cancer patients, enabling improved treatment planning when compared to MRI alone.
本研究旨在评估和比较整合 PET/MRI 与 MRI 单独用于原发性宫颈癌局部肿瘤评估和全身肿瘤分期的诊断性能。此外,还评估了这两种成像方式对进一步的患者管理的相应影响。
前瞻性纳入 53 例经组织病理学证实的原发性宫颈癌患者进行全身 18F-FDG PET/MRI 检查。两名有经验的医生对 MRI 数据进行了分析,达成共识后,再进行一次 PET/MRI 数据集的二次读取。读者被要求根据第 7 版 AJCC 分期手册进行专门的 TNM 分期。随后,在模拟的跨学科肿瘤委员会中讨论 MRI 和 PET/MRI 的结果,并记录基于两种成像方式的治疗决策。组织病理学和横断面成像随访的结果作为参考标准。
PET/MRI 可正确确定 53 例中的 45 例(85%)的 T 分期,而 MRI 单独可正确识别 46 例(87%)中的肿瘤分期。在 53 例患者中,有 24 例存在淋巴结转移。对于检测淋巴结阳性患者,PET/MRI 的灵敏度、特异性和准确性分别为 83%、90%和 87%。MRI 单独的相应值分别为 71%、83%和 77%。此外,PET/MRI 对远处转移的检测优于 MRI 单独(灵敏度:87%比 67%,特异性:92%比 90%,诊断准确性:91%比 83%)。在两种成像方式分期结果不一致的患者中,PET/MRI 可使更多(n=9)患者的治疗建议正确,而 MRI 单独则可使更多(n=3)患者的治疗建议正确。
本研究结果表明,整合 PET/MRI 成像可成功应用于宫颈癌患者的全身肿瘤分期,与 MRI 单独相比,可改善治疗计划。